Market closedNon-fractional
Glaukos/GKOS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Glaukos
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Ticker
GKOS
Sector
Healthcare
Trading on
NYSE
Industry
Health Care Equipment and Supplies
Headquarters
Aliso Viejo, United States
Employees
907
Website
www.glaukos.com
Glaukos Metrics
BasicAdvanced
$6.4B
Market cap
-
P/E ratio
-$2.88
EPS
1.08
Beta
-
Dividend rate
Price and volume
Market cap
$6.4B
Beta
1.08
Financial strength
Current ratio
5.38
Quick ratio
4.422
Long term debt to equity
85.088
Total debt to equity
85.088
Interest coverage (TTM)
-8.87%
Management effectiveness
Return on assets (TTM)
-7.95%
Return on equity (TTM)
-29.37%
Valuation
Price to revenue (TTM)
17.609
Price to book
12.91
Price to tangible book (TTM)
56.69
Price to free cash flow (TTM)
-76.466
Growth
Revenue change (TTM)
12.92%
Earnings per share change (TTM)
-1.29%
3-year revenue growth (CAGR)
11.17%
3-year earnings per share growth (CAGR)
16.16%
What the Analysts think about Glaukos
Analyst Ratings
Majority rating from 14 analysts.
Glaukos Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$86M
4.01%
Net income
-$41M
11.17%
Profit margin
-47.66%
6.88%
Glaukos Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.55
-$0.50
-$0.63
-$0.70
-
Expected
-$0.55
-$0.55
-$0.55
-$0.57
-$0.51
Surprise
-0.81%
-8.88%
14.58%
21.92%
-
Glaukos News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Glaukos stock?
Glaukos (GKOS) has a market cap of $6.4B as of July 27, 2024.
What is the P/E ratio for Glaukos stock?
The price to earnings (P/E) ratio for Glaukos (GKOS) stock is 0 as of July 27, 2024.
Does Glaukos stock pay dividends?
No, Glaukos (GKOS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Glaukos dividend payment date?
Glaukos (GKOS) stock does not pay dividends to its shareholders.
What is the beta indicator for Glaukos?
Glaukos (GKOS) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Glaukos stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.